sars-cov-2 |
33 |
diabetes |
32 |
covid-19 |
25 |
humans |
23 |
type 2 diabetes |
23 |
adult |
21 |
middle aged |
21 |
osteoporosis |
19 |
female |
18 |
male |
18 |
chinese |
17 |
thyroid function tests |
17 |
aged |
16 |
bone mineral density |
16 |
diabetes mellitus |
16 |
obesity |
15 |
primary care |
14 |
stroke |
14 |
thyroid gland |
13 |
microvascular complications |
12 |
autoimmunity |
11 |
bone density |
11 |
cardiovascular disease |
11 |
clinical vertebral fractures |
11 |
fatty liver disease |
11 |
graves disease |
11 |
hip fractures |
11 |
hyperthyroidism |
11 |
hypothyroidism |
11 |
long covid |
11 |
mafld (metabolic associated fatty liver disease) |
11 |
osteoporotic fractures |
11 |
overweight |
11 |
population based study |
11 |
sars-cov-2 infection |
11 |
thyroid dysfunction |
11 |
thyroiditis |
11 |
type 2 diabetes mellitus |
11 |
upper limb fractures |
11 |
advanced glycation end-products |
10 |
atrial fibrillation |
10 |
body mass index |
10 |
chinese medicine |
10 |
clinical trial |
10 |
epidemiology |
10 |
pragmatic |
10 |
prospective studies |
10 |
asian-specific |
9 |
cancer |
9 |
cardiovascular complications |
9 |
euthyroid sick syndromes |
9 |
exome-chip association analysis |
9 |
genotype |
9 |
infection |
9 |
insulin resistance - physiology |
9 |
medical sciences |
9 |
pax4 |
9 |
pharmacoepidemiology |
9 |
prediabetes |
9 |
risk factors |
9 |
risk prediction model |
9 |
bronchiectasis |
8 |
ectopic acth syndrome |
8 |
interferon beta-1b |
8 |
misconception |
8 |
perception |
8 |
predictive value of tests |
8 |
prognosis |
8 |
qualitative |
8 |
smoking cessation |
8 |
theory of planned behaviour |
8 |
autoantibodies |
7 |
blood glucose - analysis |
7 |
blood pressure |
7 |
cardiovascular diseases |
7 |
case-control studies |
7 |
cilia |
7 |
complications |
7 |
double-blind method |
7 |
dpp4 inhibitor |
7 |
enzyme-linked immunosorbent assay |
7 |
fib-4 |
7 |
glomerular filtration rate |
7 |
mendelian randomization |
7 |
mortality |
7 |
nfs |
7 |
polymorphism, single nucleotide |
7 |
post–acute covid-19 syndrome |
7 |
risk |
7 |
sglt2 inhibitor |
7 |
statins |
7 |
transmission electronic microscopy |
7 |
adiponectin |
6 |
adiponectin - blood |
6 |
adiposity - physiology |
6 |
albuminuria |
6 |
allele |
6 |
animal cell |
6 |
anti-coagulant |
6 |
blood glucose - metabolism |
6 |
blood pressure - physiology |
6 |
bone metabolism |
6 |
c-reactive protein |
6 |
calcium |
6 |
chemicals and cas registry numbers |
6 |
china - epidemiology |
6 |
ciliary central microtubular orientation |
6 |
clinical trials |
6 |
cohort studies |
6 |
complementary medicine |
6 |
diabetes & endocrinology |
6 |
diabetes mellitus, type 2 - blood - drug therapy |
6 |
diabetic nephropathy & vascular disease |
6 |
doac |
6 |
epidemiological studies |
6 |
follow-up studies |
6 |
glucose tolerance test |
6 |
glyburide - therapeutic use |
6 |
glycosylation end products, advanced - blood |
6 |
hypertension |
6 |
hypertension - blood - epidemiology |
6 |
hypoglycemic agents - therapeutic use |
6 |
insulin resistance |
6 |
lipids - blood |
6 |
messenger rna |
6 |
meta-analysis |
6 |
mineral metabolism |
6 |
nephrology |
6 |
obesity - blood - complications |
6 |
opportunistic case-finding |
6 |
prediction |
6 |
rage |
6 |
receptors, immunologic - blood - drug effects |
6 |
risk prediction models |
6 |
soluble receptor for advanced glycation end-products |
6 |
thiazolidinedione |
6 |
thiazolidinediones - therapeutic use |
6 |
transcription factor gata 2 |
6 |
vitamin d |
6 |
administration, inhalation |
5 |
aged, 80 and over |
5 |
aldosterone synthase deficiency |
5 |
androstadienes - administration & dosage |
5 |
asian continental ancestry group |
5 |
avascular necrosis |
5 |
bmd |
5 |
bone turnover markers |
5 |
bronchiectasis - drug therapy |
5 |
cholesterol - blood |
5 |
clinical outcomes |
5 |
continuous glucose monitoring |
5 |
diagnosis, differential |
5 |
drug utilization |
5 |
endoscopic ultrasound |
5 |
endothelial progenitor cells |
5 |
end‐ |
5 |
familial hypercholesterolemia |
5 |
follow-up |
5 |
forced expiratory volume - physiology |
5 |
fracture |
5 |
global healthsales |
5 |
glucocorticoids |
5 |
health preference |
5 |
health-related quality of life |
5 |
heart disease |
5 |
hemoglobin a, glycosylated - analysis |
5 |
hong kong |
5 |
hypoaldosteronism |
5 |
hypophosphatemia - etiology |
5 |
inhaled corticosteroid therapy |
5 |
insulinoma |
5 |
intermittent hypoxia |
5 |
lipase - blood |
5 |
lipid-modifying agents |
5 |
lipoproteins, hdl - blood |
5 |
multiple endocrine neoplasia |
5 |
nitric oxide |
5 |
nomogram |
5 |
paraganglioma |
5 |
pheochromocytoma |
5 |
pseudomonas aeruginosa |
5 |
public health |
5 |
radio frequency ablation |
5 |
real-world evidence |
5 |
salt-wasting |
5 |
sars |
5 |
stage renal disease |
5 |
succinate dehydrogenase |
5 |
triglyceride |
5 |
triglycerides - blood |
5 |
vertebral fracture |
5 |
vital capacity |
5 |
2022 who classification |
4 |
25-hydroxyvitamin d |
4 |
acth precursor |
4 |
acth syndrome, ectopic - complications - diagnosis |
4 |
adrenocorticotropic hormone - analysis |
4 |
alkaline phosphatase - blood |
4 |
alkaline phosphatase - metabolism |
4 |
anti-diabetic agents |
4 |
anti-hypertensive |
4 |
anti-obesity agents - therapeutic use |
4 |
apolipoprotein e polymorphism |
4 |
association |
4 |
astragalus |
4 |
atypical femoral fractures |
4 |
binding sites - genetics |
4 |
biological markers - blood |
4 |
bisphosphonates |
4 |
bone density - genetics |
4 |
bone health |
4 |
bone metastases |
4 |
bone neoplasms - complications - diagnosis |
4 |
bone neoplasms - secondary |
4 |
caffeine |
4 |
carrier proteins - blood |
4 |
cascade screening |
4 |
cdx1 |
4 |
cell adhesion molecules - genetics - metabolism |
4 |
china |
4 |
china - ethnology |
4 |
cholesterol |
4 |
cholesterol ester transfer proteins |
4 |
chronic kidney disease |
4 |
coffee |
4 |
coronary artery disease |
4 |
covid-19 vaccines |
4 |
covid‐19 |
4 |
cpap treatment |
4 |
cross-over studies |
4 |
cushing syndrome - etiology |
4 |
cushing’s syndrome |
4 |
cva |
4 |
delayed-action preparations |
4 |
diabetes mellitus - drug therapy |
4 |
diabetes mellitus type 1 |
4 |
diabetes mellitus, type 2 |
4 |
diabetes mellitus, type 2 - blood - complications |
4 |
diabetes mellitus, type 2 - blood - drug therapy - enzymology |
4 |
dietary fats - metabolism |
4 |
dipeptidyl-peptidase iv inhibitors |
4 |
dyslipidaemia |
4 |
early detection |
4 |
enzyme inhibitors - therapeutic use |
4 |
epstein- barr virus |
4 |
falls |
4 |
fatty acids, nonesterified - blood |
4 |
forearm - abnormalities |
4 |
fractures, bone |
4 |
free fatty acids |
4 |
gene frequency |
4 |
genetic association |
4 |
genetic predisposition to disease |
4 |
giant cell tumor of bone - complications - diagnosis |
4 |
glucagon-like peptide-1 receptor agonists |
4 |
glycemic index |
4 |
glycogenic hepatopathy |
4 |
glycoproteins |
4 |
graves' disease |
4 |
herpesvirus 4, human - isolation & purification |
4 |
hip structure analysis |
4 |
hkos score |
4 |
homeodomain proteins - metabolism |
4 |
hospitalization |
4 |
hyperglycemia - genetics |
4 |
hyperlipidemias - drug therapy |
4 |
hyperparathyroidism - complications - diagnosis |
4 |
hypertriglyceridemia - blood - complications |
4 |
insulin - blood |
4 |
insulin sensitivity |
4 |
insulin-independent |
4 |
insulin-like growth factor i - analysis |
4 |
integrative medicine |
4 |
ischemic stroke |
4 |
lactones - therapeutic use |
4 |
ldl receptor |
4 |
ldl-c |
4 |
lipase inhibitor |
4 |
lipoproteins |
4 |
lipoproteins - blood |
4 |
lipoproteins, ldl - blood |
4 |
liver function tests |
4 |
low-density lipoprotein |
4 |
metabolomics |
4 |
metabolomics study |
4 |
model recalibration |
4 |
nasopharyngeal carcinoma |
4 |
nasopharyngeal neoplasms - complications - diagnosis |
4 |
nitric oxide synthase type iii - genetics |
4 |
non-alcoholic fatty liver disease |
4 |
non-diabetic men |
4 |
non-functioning pituitary neuroendocrine tumours |
4 |
obstructive sleep apnoea |
4 |
octreotide - therapeutic use |
4 |
osteitis deformans - blood - diagnosis - pathology - therapy |
4 |
osteitis deformans - diagnosis |
4 |
osteomalacia - etiology |
4 |
osteoporotic fractures - genetics - physiopathology |
4 |
osteosclerosis - diagnosis |
4 |
pancreatic tumor |
4 |
parathyroid hormone |
4 |
parathyroidectomy |
4 |
peptide fragments - blood |
4 |
periostin |
4 |
pitnet classification |
4 |
pituitary adenoma |
4 |
polymorphism, genetic |
4 |
postprandial lipemia |
4 |
postprandial period |
4 |
postprandial period - drug effects |
4 |
pre-diabetes |
4 |
prevalence |
4 |
primary prevention |
4 |
protein binding - genetics |
4 |
reference values |
4 |
remnant-like lipoproteins |
4 |
replication |
4 |
risk estimation |
4 |
serum calcium |
4 |
serum metabolites |
4 |
severity of sleep disordered breathing |
4 |
sleep apnea syndromes - blood - physiopathology |
4 |
sleep apnea, obstructive - blood - physiopathology - therapy |
4 |
sodium-glucose cotransporter 2 inhibitors |
4 |
sodium-glucose transporter 2 inhibitors |
4 |
sodium–glucose co-transporter type 2 inhibitors |
4 |
soft tissue neoplasms - complications - diagnosis |
4 |
somatostatin - analogs & derivatives |
4 |
spinal fractures - genetics - physiopathology |
4 |
statin |
4 |
threshold level |
4 |
trabecular bone score |
4 |
transcription factors |
4 |
triglyceride-rich lipoprotein remnants |
4 |
validation studies |
4 |
vitamin d - therapeutic use |
4 |
vitamin d binding protein |
4 |
vitamin d insufficiency |
4 |
weight loss |
4 |
yolk sac tumor |
4 |
3t3-l1 cells |
3 |
absorptiometry, photon - methods |
3 |
acromegaly - blood |
3 |
acromegaly - blood - surgery |
3 |
acromegaly - complications - drug therapy - pathology |
3 |
acromegaly - drug therapy |
3 |
adipose tissue |
3 |
advanced glycation end products |
3 |
akap11 |
3 |
albuminuria - drug therapy |
3 |
alleles |
3 |
analysis of variance |
3 |
animals |
3 |
anthropometry |
3 |
antineoplastic agents - therapeutic use |
3 |
antineoplastic agents, hormonal - therapeutic use |
3 |
aorta - cytology - metabolism |
3 |
apob gene |
3 |
apolipoprotein a-i - analysis |
3 |
apolipoprotein a-i - metabolism |
3 |
apolipoprotein e |
3 |
asian |
3 |
asian continental ancestry group - genetics - statistics and numerical data |
3 |
body composition |
3 |
body fat |
3 |
brachial artery - physiopathology |
3 |
bronchiectasis - pathology |
3 |
c-reactive protein - metabolism |
3 |
calcium blood level |
3 |
causality |
3 |
cells, cultured |
3 |
cephalometry |
3 |
chinese postmenopausal women |
3 |
cholesterol efflux |
3 |
cholesterol, hdl - blood |
3 |
chronic disease |
3 |
cilia - physiology - ultrastructure |
3 |
codon, nonsense |
3 |
cross-sectional study |
3 |
diabetes mellitus - blood - diet therapy - drug therapy - epidemiology - ethnology |
3 |
diabetes mellitus - epidemiology - ethnology - therapy |
3 |
diabetes mellitus, type 2 - blood |
3 |
diabetes mellitus, type 2 - blood - diagnosis - epidemiology |
3 |
diabetes mellitus, type 2 - blood - physiopathology - ultrasonography |
3 |
diabetic nephropathy |
3 |
diet therapy |
3 |
different intervention thresholds |
3 |
diseases in twins - genetics |
3 |
dna mutational analysis - methods |
3 |
endothelium, vascular - cytology - physiopathology - ultrasonography |
3 |
estradiol - blood |
3 |
european continental ancestry group |
3 |
fatty liver |
3 |
fibroblast growth factor 21 |
3 |
follicle stimulating hormone (fsh) |
3 |
follicle stimulating hormone - blood |
3 |
fracture incidence |
3 |
fracture prevention |
3 |
frameshift mutation |
3 |
frax with nhanes t-score |
3 |
genetic predisposition to disease - ethnology - genetics |
3 |
genetic spectrum |
3 |
genetic variation - genetics |
3 |
germ-line mutation |
3 |
glucokinase - genetics |
3 |
glucose intolerance - blood - diagnosis - epidemiology |
3 |
glucose intolerance - genetics |
3 |
glycosylated hemoglobin a |
3 |
growth hormone - blood |
3 |
handgrip strength |
3 |
hong kong - epidemiology |
3 |
human growth hormone - blood |
3 |
human growth hormone - secretion |
3 |
hyperglycemia - blood - diagnosis - epidemiology |
3 |
hypoglycemic agents - administration and dosage - therapeutic use |
3 |
hypogonadism - blood - drug therapy |
3 |
insulin - administration and dosage - therapeutic use |
3 |
insulin secretion |
3 |
intercellular signaling peptides and proteins |
3 |
intercellular signaling peptides and proteins - blood |
3 |
interferons |
3 |
ldlr gene |
3 |
leptin - blood |
3 |
lipase - metabolism |
3 |
lipid metabolism |
3 |
lipoprotein glomerulopathy |
3 |
lipoproteins - metabolism |
3 |
lipoproteins, hdl - metabolism |
3 |
liver - enzymology |
3 |
losartan - therapeutic use |
3 |
luteinizing hormone - blood |
3 |
mc3t3-e1 |
3 |
melanoma |
3 |
melanoma - diagnosis - secondary - surgery |
3 |
menopause |
3 |
metabolic syndrome x - diet therapy - drug therapy - epidemiology - ethnology |
3 |
metastasis |
3 |
mice |
3 |
microscopy, electron, transmission |
3 |
microtubular defects |
3 |
microtubules |
3 |
mineralization |
3 |
multimorbidity |
3 |
multiple endocrine neoplasia type 1 - genetics |
3 |
mutation, missense |
3 |
nasal mucosa - cytology - ultrastructure |
3 |
nephrotic syndrome |
3 |
nitric oxide - biosynthesis |
3 |
nutrition surveys |
3 |
obesity - diagnosis - ethnology |
3 |
octreotide - administration & dosage |
3 |
osteogenesis |
3 |
osteoporosis - blood - ethnology - genetics |
3 |
pathogenesis |
3 |
pedigree |
3 |
pituitary |
3 |
pituitary neoplasms - diagnosis - secondary - surgery |
3 |
polymorphism |
3 |
polysomnography |
3 |
post-acute covid-19 syndrome |
3 |
promoter regions, genetic - genetics |
3 |
protein-serine-threonine kinases - genetics |
3 |
proteins - metabolism - pharmacology |
3 |
proteinuria |
3 |
rankl |
3 |
receptors, cell surface - metabolism |
3 |
receptors, immunologic - blood |
3 |
regression analysis |
3 |
retrospective studies |
3 |
risk stratification |
3 |
sensitivity and specificity |
3 |
sglt2 inhibitors |
3 |
skin neoplasms - pathology - surgery |
3 |
sleep apnea syndromes - complications - drug therapy - pathology |
3 |
spirometry |
3 |
statin therapy |
3 |
statistics, nonparametric |
3 |
testosterone - blood - therapeutic use |
3 |
time factors |
3 |
tomography, x-ray computed |
3 |
total cholesterol |
3 |
transsphenoidal approach |
3 |
ubiquitin-protein ligases |
3 |
united states - epidemiology |
3 |
vaccines |
3 |
vasodilation |
3 |
waist circumference |
3 |
acromegaly |
2 |
acromegaly - blood - drug therapy |
2 |
administration, cutaneous |
2 |
adolescent |
2 |
affect - drug effects |
2 |
age of onset |
2 |
aging - genetics - metabolism |
2 |
all-cause mortality |
2 |
angiotensin ii receptor antagonist |
2 |
angiotensin receptor antagonists |
2 |
angiotensin-converting enzyme |
2 |
angiotensinogen |
2 |
anti-inflammatory activity |
2 |
anti-inflammatory agents - therapeutic use |
2 |
anti-oxidative activity |
2 |
anticholesteremic agents - pharmacology |
2 |
anticholesteremic agents - therapeutic use |
2 |
antigens, cd36 - genetics |
2 |
antithyroid agents - therapeutic use |
2 |
apolipoproteins - blood |
2 |
apolipoproteins b - analysis |
2 |
asian continental ancestry group - genetics |
2 |
atherosclerosis - blood - etiology |
2 |
atrial natriuretic factor - genetics |
2 |
atrial natriuretic peptide |
2 |
blood coagulation - drug effects |
2 |
brachial artery - ultrasonography |
2 |
bromocriptine - therapeutic use |
2 |
c-peptide |
2 |
c-peptide - blood |
2 |
c-reactive protein - analysis - antagonists & inhibitors |
2 |
carbamylation |
2 |
cardiovascular outcome |
2 |
carrier proteins - genetics |
2 |
centrifugation, density gradient |
2 |
cerebrotendinous xanthomatosis |
2 |
cholesterol, ldl - analysis |
2 |
cholesteryl ester transfer protein |
2 |
copper - chemistry |
2 |
coronary disease - epidemiology - prevention and control |
2 |
coronary heart disease |
2 |
cyanate |
2 |
cyp27a1 |
2 |
cytochrome p-450 cyp27a1 |
2 |
deoxyribonuclease hpaii - genetics |
2 |
diabetes mellitus - blood - classification - drug therapy - immunology |
2 |
diabetes mellitus, type 2 - blood - complications - physiopathology |
2 |
diabetes mellitus, type 2 - blood - immunology |
2 |
diabetes mellitus, type 2 - blood - physiopathology |
2 |
diabetes mellitus, type 2 - complications - diagnosis |
2 |
diabetes mellitus, type 2 - drug therapy - physiopathology |
2 |
diabetes mellitus, type 2 - drug therapy - physiopathology - ultrasonography |
2 |
diabetes mellitus, type 2 - physiopathology |
2 |
diabetic ketoacidosis - blood - immunology |
2 |
diabetic nephropathies |
2 |
dihydrotestosterone - blood |
2 |
dinoprost - analogs & derivatives - blood |
2 |
disease progression |
2 |
dna - analysis |
2 |
doubling of creatinine |
2 |
electrophoresis, polyacrylamide gel |
2 |
endocrinology |
2 |
endothelial dysfunction |
2 |
endothelium, vascular - drug effects - physiopathology - ultrasonography |
2 |
endothelium, vascular - physiology - physiopathology |
2 |
endothelium, vascular - physiology - ultrasonography |
2 |
endothelium, vascular - physiopathology |
2 |
fatty acids, monounsaturated - pharmacology |
2 |
fibrinolysis - drug effects |
2 |
fibroblast growth factor-21 |
2 |
galectin-3 |
2 |
gene |
2 |
gene deletion |
2 |
gene expression regulation |
2 |
genetic markers |
2 |
genetic testing |
2 |
genetic variation |
2 |
genomewide association studies |
2 |
glycoxidized low-density lipoprotein |
2 |
graves disease - blood - drug therapy |
2 |
growth hormone |
2 |
growth hormone - blood - drug effects |
2 |
hdl dysfunction |
2 |
hemoglobin a, glycosylated - metabolism |
2 |
hepatic lipase |
2 |
heptanoic acids - therapeutic use |
2 |
heterozygote |
2 |
high-lipoprotein cholesterol |
2 |
histocompatibility testing |
2 |
hla-dr3 antigen - genetics |
2 |
homocysteine |
2 |
homocysteine - blood |
2 |
homozygote |
2 |
hong kong - ethnology |
2 |
hong kong chinese |
2 |
hormone antagonists - therapeutic use |
2 |
hormone replacement therapy |
2 |
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
2 |
hypercholesterolemia - blood - complications |
2 |
hyperhomocysteinemia - blood - complications - physiopathology |
2 |
hyperlipidemias - blood - drug therapy - epidemiology |
2 |
hyperlipidemias - complications - genetics |
2 |
hypertension - blood - genetics |
2 |
hypertension - enzymology - genetics |
2 |
hypogonadism - blood - drug therapy - physiopathology - psychology |
2 |
hypogonadism - drug therapy - metabolism |
2 |
hypothyroidism - blood - drug therapy - etiology |
2 |
incident macroalbuminuria |
2 |
indoles - pharmacology |
2 |
instrumental variables analysis |
2 |
insulin - therapeutic use |
2 |
insulin-like growth factor i - drug effects - metabolism |
2 |
insulin-like growth factor-i |
2 |
intracellular lipid |
2 |
kinetics |
2 |
linear models |
2 |
lipid peroxidation |
2 |
lipid-modifying therapy |
2 |
lipoprotein |
2 |
lipoprotein lipase |
2 |
lipoprotein lipase - blood |
2 |
lipoproteins, ldl - blood - drug effects |
2 |
lipoproteins, ldl - physiology |
2 |
liver - enzymology - metabolism |
2 |
longitudinal studies |
2 |
macrophage |
2 |
macrophages - chemistry |
2 |
masturbation - epidemiology |
2 |
microalbuminuria |
2 |
microsomal triglyceride transfer protein |
2 |
monocytes |
2 |
myeloperoxidase |
2 |
myocardial infarction - enzymology - genetics |
2 |
nandrolone - adverse effects - analogs and derivatives - therapeutic use |
2 |
nitroglycerin - pharmacology |
2 |
normocholesterolemic tendon xanthomas |
2 |
novel splicing mutation |
2 |
obstructive sleep apnea |
2 |
oxidative stress |
2 |
peptidyl-dipeptidase a - genetics |
2 |
placebos |
2 |
point mutation |
2 |
polymerase chain reaction |
2 |
polymorphism, restriction fragment length |
2 |
progression of renal failure |
2 |
pyrroles - therapeutic use |
2 |
radioimmunoassay |
2 |
receptors, immunologic - genetics |
2 |
receptors, scavenger |
2 |
renal fibrosis |
2 |
reverse transcriptase polymerase chain reaction |
2 |
rna splicing |
2 |
scavenger receptor |
2 |
scavenger receptors, class a |
2 |
scavenger receptors, class b |
2 |
sexual behavior - drug effects |
2 |
sleep apnea, obstructive - blood - complications |
2 |
small dense low density lipoprotein |
2 |
smoking |
2 |
steroid hydroxylases - genetics |
2 |
sterol 27-hydroxylase |
2 |
testosterone - administration & dosage - metabolism |
2 |
thyroid diseases - blood |
2 |
triglycerides - antagonists & inhibitors - blood |
2 |
uraemia |
2 |
vasodilation - drug effects |
2 |
vasodilation - physiology |
2 |
vasodilator agents - pharmacology |
2 |
xanthomatosis, cerebrotendinous - genetics |
2 |
absorptiometry, photon - methods - standards |
1 |
acute disease |
1 |
acute-phase proteins - metabolism |
1 |
acute-phase reaction - etiology |
1 |
acute-phase response |
1 |
adenosine |
1 |
adenosine - analogs & derivatives - metabolism - pharmacology |
1 |
adenosine diphosphate - antagonists & inhibitors - pharmacology |
1 |
adenosine receptors |
1 |
adenosine triphosphate binding cassette transporters |
1 |
adenosine-5'-(n-ethylcarboxamide) |
1 |
adrenal adenoma |
1 |
adrenal hyperplasia |
1 |
advanced glycation end products (ages) |
1 |
advanced glycation end-product (age) |
1 |
aequorin - metabolism |
1 |
aggregation |
1 |
albuminuria - blood |
1 |
albuminuria - blood - metabolism |
1 |
antihypertensive agents - therapeutic use |
1 |
antioxidants - metabolism |
1 |
aorta - enzymology |
1 |
apolipoprotein a-i - pharmacology |
1 |
apolipoprotein ai |
1 |
apolipoproteins b - metabolism |
1 |
apolipoproteins e - blood |
1 |
aryldialkylphosphatase - metabolism |
1 |
asia - epidemiology |
1 |
asian continental ancestry group - classification - statistics and numerical data |
1 |
atorvastatin |
1 |
atp |
1 |
atp binding cassette transporters |
1 |
atp-binding cassette transporter a1 |
1 |
atp-binding cassette transporters - biosynthesis - blood - genetics |
1 |
atp-binding cassette transporters - blood - genetics - metabolism |
1 |
atp-binding cassette transporters - metabolism |
1 |
awareness |
1 |
binding sites |
1 |
biological transport |
1 |
biomarker |
1 |
blood platelets - chemistry - physiology |
1 |
blood platelets - drug effects |
1 |
blood platelets - drug effects - metabolism - physiology |
1 |
blood platelets - drug effects - physiology |
1 |
blood platelets - enzymology |
1 |
blotting, western - methods |
1 |
body constitution |
1 |
body weight |
1 |
body weight - ethnology |
1 |
body weight gain |
1 |
brachial artery - physiopathology - ultrasonography |
1 |
c-reactive protein - analysis - pharmacology |
1 |
c-reactive protein - antagonists & inhibitors - drug effects - metabolism |
1 |
calcium - blood |
1 |
calcium - metabolism |
1 |
camp |
1 |
carbohydrate intake |
1 |
cardiovascular diseases - etiology |
1 |
carrier proteins - metabolism |
1 |
cat diseases - drug therapy |
1 |
catecholamines - analysis |
1 |
cats |
1 |
cell line, tumor |
1 |
cell membrane - metabolism |
1 |
cholesterol - blood - metabolism |
1 |
cholesterol ester transfer proteins - antagonists & inhibitors |
1 |
cholesterol esters - metabolism |
1 |
cholesterol, hdl - deficiency |
1 |
cholesterol, hdl - metabolism |
1 |
cholesterol, ldl - blood |
1 |
cholesterol, ldl - metabolism |
1 |
cholestyramine |
1 |
cholestyramine resin - pharmacology |
1 |
chylomicrons - blood |
1 |
clinical prediction |
1 |
collagen |
1 |
collagen - pharmacology |
1 |
combined modality therapy |
1 |
congresses as topic |
1 |
coronary artery |
1 |
coronary artery disease - blood - etiology |
1 |
coronary disease - blood - diagnosis |
1 |
coronary disease - etiology |
1 |
creatinine clearance |
1 |
cyclic amp |
1 |
cyclic amp - blood |
1 |
dense ldl |
1 |
diabetes mellitus - drug therapy - veterinary |
1 |
diabetes mellitus, type 1 - complications - metabolism |
1 |
diabetes mellitus, type 2 - blood - ethnology |
1 |
diabetes mellitus, type 2 - blood - genetics |
1 |
diabetes mellitus, type 2 - blood - metabolism |
1 |
diabetes mellitus, type 2 - blood - physiopathology - therapy |
1 |
diabetes mellitus, type 2 - complications - immunology |
1 |
diabetes mellitus, type 2 - diagnosis - drug therapy |
1 |
diabetes mellitus, type 2 - drug therapy |
1 |
diabetes mellitus, type 2 - enzymology - genetics - physiopathology |
1 |
diabetes mellitus, type 2 - metabolism |
1 |
diabetic angiopathies - blood - epidemiology - physiopathology |
1 |
diabetic diet |
1 |
diabetic nephropathies - blood |
1 |
diabetic nephropathies - blood - physiopathology |
1 |
diabetic nephropathies - drug therapy |
1 |
diabetic nephropathies - metabolism |
1 |
diabetic retinopathy - blood - complications - metabolism |
1 |
dietary fats |
1 |
dyslipidemia |
1 |
dyslipidemias - drug therapy - epidemiology - etiology - therapy |
1 |
eating - physiology |
1 |
end-stage renal disease |
1 |
endothelial cells - metabolism |
1 |
endothelial lipase |
1 |
endothelium, vascular - enzymology |
1 |
endothelium, vascular - physiopathology - ultrasonography |
1 |
england |
1 |
enzyme-linked immunosorbent assay - methods |
1 |
epoprostenol - pharmacology |
1 |
familial hypercholesterolaemia |
1 |
fasting |
1 |
fasting - blood |
1 |
financial management - economics |
1 |
forskolin - pharmacology |
1 |
gene expression |
1 |
glycation end products |
1 |
glycosylation |
1 |
glycoxidized ldl |
1 |
gtp-binding proteins - physiology |
1 |
hdl |
1 |
hepatocytes - metabolism |
1 |
high density lipoprotein |
1 |
high density lipoprotein cholesterol |
1 |
homeostasis model assessment index |
1 |
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology |
1 |
hyperlipoproteinemia type ii - blood |
1 |
hyperlipoproteinemia type ii - blood - enzymology |
1 |
hyperlipoproteinemia type ii - blood - physiopathology |
1 |
hyperlipoproteinemia type ii - metabolism |
1 |
hypertriglyceridaemia |
1 |
hypertriglyceridemia |
1 |
hypertriglyceridemia - blood - physiopathology |
1 |
hypertriglyceridemia - complications - epidemiology - therapy |
1 |
hypertriglyceridemia - complications - genetics - metabolism - therapy |
1 |
hypoglycemic agents - administration & dosage - therapeutic use |
1 |
hypolipidemic agents - pharmacology |
1 |
hypolipidemic agents - therapeutic use |
1 |
immunoassay |
1 |
inflammation |
1 |
inositol 1 |
1 |
inositol 1,4,5 trisphosphate |
1 |
inositol 1,4,5-trisphosphate - metabolism |
1 |
insulin |
1 |
insulin - administration & dosage - therapeutic use |
1 |
insulin - blood - secretion |
1 |
intravascular ultrasound |
1 |
islets of langerhans - secretion |
1 |
lectin-like oxidized low density lipoprotein receptor |
1 |
lectin-like oxidized low density lipoprotein receptor-1 (lox-1) |
1 |
leukocytes, mononuclear - metabolism |
1 |
lipase - blood - genetics - metabolism |
1 |
lipase - genetics - metabolism |
1 |
lipoprotein lipase - metabolism |
1 |
lipoproteins, hdl - drug effects - metabolism |
1 |
lipoproteins, ldl - metabolism |
1 |
liver - metabolism |
1 |
low density lipoprotein subfractions |
1 |
lung neoplasms - drug therapy |
1 |
lymphangioleiomyomatosis - drug therapy |
1 |
macrophages - metabolism |
1 |
mammalian target of rapamycin (mtor) |
1 |
medical staff, hospital |
1 |
medroxyprogesterone - administration & dosage |
1 |
membrane proteins - blood |
1 |
membrane proteins - blood - pharmacology |
1 |
metabolic syndrome |
1 |
metabolic syndrome x - complications - epidemiology - therapy |
1 |
models, biological |
1 |
multivariate analysis |
1 |
nephropathy |
1 |
niacin - pharmacology |
1 |
non-insulin-dependent diabetes mellitus |
1 |
noradrenaline |
1 |
nε-(carboxymethyl)lysine |
1 |
obesity - classification - diagnosis - ethnology |
1 |
orphan nuclear receptors - agonists |
1 |
oxidized ldl |
1 |
oxysterols |
1 |
peritoneal dialysis |
1 |
peroxisome proliferator-activated receptors - agonists |
1 |
phosphatidylcholines - blood |
1 |
phospholipid transfer protein |
1 |
phospholipid transfer proteins |
1 |
phospholipid transfer proteins - blood |
1 |
phospholipid transfer proteins - blood - pharmacology |
1 |
phosphoric diester hydrolases - blood |
1 |
platelet activation - physiology |
1 |
platelet aggregation |
1 |
platelet aggregation - drug effects |
1 |
platelet aggregation - drug effects - physiology |
1 |
platelet aggregation inhibitors - pharmacology |
1 |
platelet. |
1 |
platelets |
1 |
postprandial lipaemia |
1 |
postprandial lipoprotein metabolism |
1 |
pre-β1 hdl |
1 |
primary aldosteronism |
1 |
progesterone congeners - administration & dosage |
1 |
proinsulin - blood |
1 |
proinsulin - blood - secretion |
1 |
protein precursors - blood - secretion |
1 |
proteinuria - blood - metabolism |
1 |
quinolines |
1 |
rabbits |
1 |
receptors |
1 |
receptors, immunologic - blood - genetics |
1 |
receptors, purinergic - metabolism |
1 |
remodeling index |
1 |
resistance |
1 |
reverse cholesterol transport |
1 |
risk factor |
1 |
rna, messenger - analysis - metabolism |
1 |
rna, messenger - blood - genetics |
1 |
rna, messenger - genetics |
1 |
saline infusion test |
1 |
scavenger receptor class b type i |
1 |
scavenger receptors, class b - biosynthesis - blood - genetics |
1 |
scavenger receptors, class b - blood - metabolism |
1 |
scavenger receptors, class b - metabolism |
1 |
scavenger receptors, class e - blood |
1 |
scavenger receptors, class e - metabolism |
1 |
serum cholesterol efflux capacity |
1 |
sex characteristics |
1 |
sex factors |
1 |
signal transduction |
1 |
signal transduction - drug effects |
1 |
small |
1 |
small dense ldl |
1 |
solubility |
1 |
soluble receptor for advanced glycation end product |
1 |
soluble receptor for advanced glycation end-product (srage) |
1 |
soluble receptors |
1 |
stroke - blood - diagnosis |
1 |
thiazolidinediones - pharmacology |
1 |
travel |
1 |
treatment outcome |
1 |
triglycerides - metabolism |
1 |
trisphosphate |
1 |
ultracentrifugation |
1 |